For 30 years, Medtronic has led the technology revolution in diabetes care. This history vividly reflects our dedication and ongoing vision to develop an “artificial pancreas”.
In 1983, we pioneered the idea of continuous insulin delivery, introducing our first insulin pump as the most innovative way to deliver insulin and help normalise glucose control for people with diabetes.
Since that time, Medtronic has remained the market leader, earning a reputation for excellence in insulin pump therapy, continuous glucose monitoring and data management.
- We were the first to launch continuous glucose monitoring products in the market and the only to offer an FDA approved device for professionals (First CE mark on 2004).
- We are working towards delivering the first artificial pancreas onto the market within the next few years.
- We are the first introducing the features of MiniMed® 640G Integrated System which can guide towards better control1 by helping to reduce hypoglycaemic episodes2 and providing personalised convenience for easier daily management of diabetes.
We are committed to refining our support services and tools to build our patients’ trust and confidence. With our advanced insulin pump therapy combined with our continuous glucose monitoring and data management products we deliver state-of-the-art diabetes management.
THE FUTURE OF DIABETES MANAGEMENT
|At Medtronic, our number one priority is the creation of an artificial pancreas – or a “closed-loop system” – which monitors glucose levels 24/7 and automatically delivers exactly the right amount of insulin.|
First with the Paradigm® Veo™ and now with the MiniMed® 640G Integrated System (features innovative technology to more closely mimic the way a healthy pancreas delivers basal insulin to the body and helps achieve better control) we are almost there. Our scientists are now focused on developing a way to regulate insulin delivery without any user intervention whatsoever.
When complete, we’re confident that the closed-loop system will transform the lives of millions of people with diabetes worldwide.
Any statements made about the company’s anticipated regulatory approvals are forward-looking statements subject to risks and uncertainties